Eli Lilly and Co
Eli Lilly’s 170% UK price hike for Mounjaro is just the start as pharma firms bow to Trump’s pricing pressures
Key Points Pharma giants are navigating U.S. President Donald Trump’s demands to bring U.S. drug prices in line with other developed nations. Eli Lilly’s decision to hike Mounjaro prices in the U.K. could spark similar moves from other firms, analysts say. The U.S. consistently pays the most in the world for many prescription drugs. Eli Lilly ‘s […]
Read More
Novo Nordisk offers diabetes drug Ozempic for less than half the price for cash-paying U.S. patients
A box of Ozempic made by Novo Nordisk, at a pharmacy in London on March 8, 2024. Hollie Adams | Reuters Novo Nordisk on Monday said it now offers cash-paying U.S. patients its blockbuster diabetes treatment Ozempic for less than half its monthly list price, as drugmakers face mounting political pressure to lower prices in […]
Read More
Eli Lilly hikes price of diabetes drug Mounjaro in UK as Trump pressures pharma to align drug costs
Mounjaro manufactured by Eli Lilly and Company packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on April 9, 2024. Nurphoto | Nurphoto | Getty Images Eli Lilly on Thursday said it is raising the list price of its blockbuster diabetes drug Mounjaro in the U.K. starting in September, as […]
Read More
The S&P 500 is on the cusp of another record. How long can this bull keep dodging danger?
A week removed from a brutal payroll report that triggered worry over a tapped consumer and a trapped Federal Reserve, the broad stock indexes are back at the cusp of all-time highs, market volatility has returned to year-to-date lows and some investors are calling off the August hurricane watch. The S & P 500’s 2.4% […]
Read More
Stocks making the biggest moves midday: Firefly Aerospace, Fortinet, Duolingo, Eli Lilly and more
Check out some of the companies making headlines in midday trading: Firefly Aerospace — Shares of the Texas-based rocket maker surged more than 50% as they debuted Thursday afternoon on the Nasdaq under the “FLY” ticker symbol. On Wednesday, the stock priced in its initial public offering at $45 each, which was above its expected […]
Read More
Stocks making the biggest moves premarket: Eli Lilly, Peloton, Intel, Duolingo and more
Check out the companies making headlines before the bell. Eli Lilly — The pharmaceutical stock dropped more than 7% despite posting a second-quarter earnings and revenue beat . The company also raised guidance for both its full-year earnings and revenue. Meantime, Eli Lilly reported that the highest dose of an experimental daily pill helped patients […]
Read More
Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar
The Eli Lilly logo is shown on one of the company’s offices in San Diego, California, on Sept. 17, 2020. Mike Blake | Reuters Eli Lilly on Thursday hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. The company raised its fiscal 2025 […]
Read More
Eli Lilly’s obesity pill led to around 12% weight loss in closely watched late-stage trial, paving way for approval
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly on Thursday said the highest dose of its daily obesity pill helped patients lose almost 12% of their body weight, or roughly 27 pounds, at 72 weeks in […]
Read More
Eli Lilly earnings are coming Thursday. Here’s what top analysts expect
Many on Wall Street expect that Novo Nordisk ‘s loss has been Eli Lilly ‘s gain, and this will be good news for the Zepbound maker’s second-quarter results. Novo Nordisk’s stock has cratered about 47% since the start of the year, as doubts emerged about the outlook for its GLP-1 drugs, Ozempic for diabetes and […]
Read More
Novo Nordisk doubles down on Trump-friendly sales strategy
Boxes of Ozempic and Wegovy made by Novo Nordisk at a pharmacy in London on March 8, 2024. Hollie Adams | Reuters Wegovy-maker Novo Nordisk said Wednesday that it was doubling down on direct-to-consumer sales as it contends with copycat compounders and Washington’s demands for lower domestic drug prices. Chief Financial Officer Karsten Munk Knudsen […]
Read More